These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 21839894)

  • 21. A comparative economic analysis of simvastatin versus atorvastatin: results of the Surrogate Marker Cost-Efficacy (SMaC) study.
    Badia X; Russo P; Attanasio E
    Clin Ther; 1999 Oct; 21(10):1788-96. PubMed ID: 10566573
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis.
    März W; Genser B; Drechsler C; Krane V; Grammer TB; Ritz E; Stojakovic T; Scharnagl H; Winkler K; Holme I; Holdaas H; Wanner C;
    Clin J Am Soc Nephrol; 2011 Jun; 6(6):1316-25. PubMed ID: 21493741
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes.
    Schwartz GG; Ganz P; Waters D; Arikian S
    Am J Cardiol; 2003 Nov; 92(9):1109-12. PubMed ID: 14583367
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial).
    Miller PS; Smith DG; Jones P
    Am J Cardiol; 2005 Jun; 95(11):1314-9. PubMed ID: 15904635
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of high-dose atorvastatin compared with usual-dose simvastatin: less than IDEAL?
    Kaul P
    Eur Heart J; 2007 Jun; 28(12):1405-6. PubMed ID: 17553925
    [No Abstract]   [Full Text] [Related]  

  • 26. [Cost-effectiveness analysis of the use of atorvastatin in patients with type 2 diabetes mellitus: a pharmacoeconomic model of the CARDS study].
    Fernández de Bobadilla J; López de Sa E; Alonso Troncoso I; Moreno Gómez R; Rubio-Terrés C; Soto Alvarez J
    An Med Interna; 2006 May; 23(5):213-9. PubMed ID: 16817698
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rosuvastatin is cost-effective compared with atorvastatin in reaching cholesterol goals.
    Hirsch M; O'donnell J; Olsson A
    Int J Cardiol; 2005 Oct; 104(3):251-6. PubMed ID: 16186052
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
    Malhotra HS; Goa KL
    Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of statins.
    Huse DM; Russell MW; Miller JD; Kraemer DF; D'Agostino RB; Ellison RC; Hartz SC
    Am J Cardiol; 1998 Dec; 82(11):1357-63. PubMed ID: 9856919
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
    Yee HS; Fong NT
    Ann Pharmacother; 1998 Oct; 32(10):1030-43. PubMed ID: 9793596
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of sevelamer versus calcium carbonate plus atorvastatin to reduce LDL in patients with chronic renal insufficiency with dyslipidemia and hyperphosphatemia.
    Brophy DF; Wallace JF; Kennedy DT; Gehr TW; Holdford DA
    Pharmacotherapy; 2000 Aug; 20(8):950-7. PubMed ID: 10939556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Cost-effectiveness of atorvastatin in the early treatment of acute coronary syndromes in Germany based on the MIRACL study].
    Lange AP; Szucs TD
    Med Klin (Munich); 2004 Sep; 99(9):500-5. PubMed ID: 15372179
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
    Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Thomason MJ; Mackness MI; Charlton-Menys V; Fuller JH;
    Lancet; 2004 Aug 21-27; 364(9435):685-96. PubMed ID: 15325833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events.
    Grover SA; Coupal L; Paquet S; Zowall H
    Arch Intern Med; 1999 Mar; 159(6):593-600. PubMed ID: 10090116
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).
    Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlöf B; Sever PS; Wedel H; Jönsson B;
    Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):29-36. PubMed ID: 15703503
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The pharmaco-economics of peri-operative statin therapy.
    Biccard BM; Sear JW; Foëx P
    Anaesthesia; 2005 Nov; 60(11):1059-63. PubMed ID: 16229688
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Switching statins in Norway after new reimbursement policy: a nationwide prescription study.
    Sakshaug S; Furu K; Karlstad Ø; Rønning M; Skurtveit S
    Br J Clin Pharmacol; 2007 Oct; 64(4):476-81. PubMed ID: 17441934
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparing the efficacy and safety of atorvastatin and simvastatin in Asians with elevated low-density lipoprotein-cholesterol--a multinational, multicenter, double-blind study.
    Wu CC; Sy R; Tanphaichitr V; Hin AT; Suyono S; Lee YT
    J Formos Med Assoc; 2002 Jul; 101(7):478-87. PubMed ID: 12353340
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes in Spain.
    Gómez-Gerique JA; Casciano R; Stern L; Rejas J
    Eur J Health Econ; 2004 Oct; 5(3):278-84. PubMed ID: 15714350
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a Primary Care setting.
    Usher-Smith JA; Ramsbottom T; Pearmain H; Kirby M
    Int J Clin Pract; 2007 Jan; 61(1):15-23. PubMed ID: 17229176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.